Clinical Validity of IntelliSpace Cognition Digital Assessment Platform in Mild Cognitive Impairment

Willem Huijbers; Gijs van Elswijk; Mandy Spaltman; Mike Cornelis; Ben Schmand; Baraa Alnaji; Maxwell Yargeau; Sarah Harlock; Ryu P. Dorn; Bela Ajtai; Erica S. Westphal; Nandor Pinter

doi:10.1101/2023.02.28.22283846

Abstract

We evaluated a digital cognitive assessment platform, Philips IntelliSpace Cognition, in a cross-sectional cohort of patients diagnosed with mild cognitive impairment (MCI). Performance on individual neuropsychological tests, cognitive domain scores, and Alzheimer’s disease (AD) specific composite scores in MCI were compared with a cohort of cognitively normal adults (CN). The cohorts were matched for age, sex, and education. The performance on all but two neuropsychological tests was worse in the MCI group. After ranking the cognitive domains by effect size, we found that the memory domain was most impaired, followed by executive functioning. The Early AD/MCI Alzheimer’s Cognitive Composite (EMACC) and Preclinical Alzheimer’s Cognitive Composite (PACC) scores were constructed from the digital tests on Philips IntelliSpace Cognition. Both AD-specific composite scores showed greater sensitivity and specificity than the Mini-Mental State Examination, as well as individual neuropsychological tests and individual cognitive domain scores. Together, these results demonstrate the diagnostic value of Philips IntelliSpace Cognition in patients with MCI.

Competing Interest Statement

WH, GvE and MS were employees of Philips Research during this study. WH is currently an employee of Biogen Digital Health. NP, SH and BA contributed to development of a white paper on clinical experience with ISC, which was funded by Philips through NeuroNet Pro LLC.

Clinical Trial

NCT04243642

Funding Statement

This study was funded by Philips Research

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the Western Institutional Review Board Copernicus Group and the internal committee for biomedical experiments of Philips. The study is registered at clinicaltrials.gov (NCT04243642).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes